Atara Biotherapeutics is a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Our commitment is to make every effort to support patients in need of treatment options.
We have designed our clinical studies to evaluate the potential of our investigational treatments in a well-defined cohort of patients with eligibility criteria that allow for appropriate assessment of safety and clinical effect. If you are interested in learning more about our ongoing clinical studies, please contact us at ClinicalStudies@atarabio.com.
We also recognize our clinical studies will not be available to all patients who have life threatening diseases and no satisfactory treatment alternatives. For these patients, we have expanded access programs for Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+ PTLD) and other EBV associated hematologic and solid tumors, as well as CMV disease. Click here to learn more about these programs.
There may also be instances where there is a significant patient need that we have not anticipated or encountered. If you would like to discuss availability of investigational drug product for a specific patient in significant need, or if you have a specific research idea, please contact us at MedInfo@atarabio.com.
ongoing clinical studies >